Loading organization details...
Loading organization details...
Source: IRS e-Filed Form 990 (from the IRS e-File system), Tax Year 2024
Total Revenue
▼$4.3M
Program Spending
80%
of total expenses go to program services
Total Contributions
$1.6M
Total Expenses
▼$4.9M
Total Assets
$12.6M
Total Liabilities
▼$1.1M
Net Assets
$11.6M
Officer Compensation
→$182.7K
Other Salaries
$1.8M
Investment Income
$262K
Fundraising
▼N/A
Source: USAspending.gov · Searched by organization name
VA/DoD Awards
$923.6K
VA/DoD Award Count
2
Funding from the Department of Veterans Affairs and/or Department of Defense.
Total Federal Funding
$14.9M
Awards Found
9
| Awarding Agency | Description | Amount | Fiscal Year | Period |
|---|---|---|---|---|
| Department of Health and Human Services | BELT: BLACKS & EXACERBATIONS ON LABA VS. TIOTROPIUM | $9.3M | FY2010 | Sep 2010 – Sep 2013 |
| Department of Health and Human Services | DUAL ANTIPLATELET THERAPY TRIAL: RESEARCH PROJECT GRANT (R01) | $1.5M | FY2009 | Sep 2009 – Feb 2011 |
| Department of Health and Human Services | CALCIUM TRANSPORT IN KIDNEY PROXIMAL TUBULE AND CALCIUM PHOSPHATE STONE FORMATION | $1.1M | FY2015 | Sep 2015 – Dec 2023 |
| Department of Health and Human Services | PESBART: EFFECTS OF PHYSICAL ENVIRONMENT AND STRESS IN BLACKS IN RELATION TO ASTH | $750K | FY2013 | Sep 2013 – Mar 2015 |
| Department of Health and Human Services | TOWARDS TREATMENT FOR THE COMPLEX PATIENT: INVESTIGATIONS OF LOW-INTENSITY FOCUSED ULTRASOUND. - OPIOID USE DISORDER WITH CO-MORBID CHRONIC PAIN AND ANXIETY (OCPA) IS A CLINICAL TRIAD ASSOCIATED WITH THE HIGHEST RISK OF OPIATE OVERDOSE DEATHS. CO-OCCURRENCE OF THESE THREE DISORDERS AMPLIFIES SYMPTOMS OF EACH AND RESULTS IN POORER TREATMENT OUTCOMES. THERE ARE SHARED NEUROBIOLOGICAL SUBSTRATES FOR THESE DISORDERS SUCH AS REWARD PROCESSING AND STRESS RESPONSE. THE ANTERIOR INSULA (AI) IS A BRAIN REGION INVOLVED IN THESE PROCESSES AS WELL AS IN CLINICAL DISORDER OF PAIN, ADDICTION, AND ANXIETY. THE AI IS UPREGULATED IN PAIN, ADDICTION AND ANXIETY DISORDERS AND IS THEREFORE A POTENTIAL THERAPEUTIC TARGET FOR NEUROMODULATION. LOW-INTENSITY FOCUSED ULTRASOUND (LIFU) IS A NONINVASIVE METHOD TO INHIBIT CORTICAL AND DEEP BRAIN REGIONS. LIFU CAN REACH DEEP BRAIN REGIONS SUCH AS THE AI WITH SPATIAL SPECIFICITY, UNLIKE TRADITIONAL NONINVASIVE NEUROMODULATION METHODS WHICH LACK SPATIAL SPECIFICITY AND DEPTH PENETRATION. LIFU CAN SELECTIVELY TARGET THE INSULA AND ITS SUBREGIONS AND PROVIDES A POTENTIALLY TRANSFORMATIVE METHOD TO REDUCE SYMPTOMS OF PAIN, OPIATE CRAVING, AND ANXIETY IN A COMPLEX PATIENT POPULATION SUCH AS OCPA. IN THE UG3 PHASE OF THIS STUDY, WE WILL ADMINISTER ONE SESSION OF INHIBITORY LIFU TO THE AI IN INDIVIDUALS WITH OCPA [OPIATE USE DISORDER, CHRONIC BACK PAIN, AND ANXIETY DISORDERS (GENERALIZED ANXIETY DISORDER, POST-TRAUMATIC STRESS DISORDER, OR SOCIAL ANXIETY DISORDER)]. THE AIM OF THIS PHASE OF THE STUDY IS TO ESTABLISH THAT LIFU VS SHAM LIFU TO AI IS SAFE AND WELL TOLERATED AS MEASURED BY ADVERSE EVENTS, CLINICAL EVALUATION AND REPEATED STRUCTURAL BRAIN MAGNETIC RESONANCE IMAGING SCANS. WE WILL ALSO GATHER PRELIMINARY DATA ON THE EFFECT OF LIFU TO AI ON OPIATE CUE-INDUCED CRAVING AND LABORATORY MEASURES OF CENTRAL SENSITIZATION(CS) WHICH OCCURS WITH PAIN CHRONICITY SUCH AS TEMPORAL SUMMATION OF PAIN AND CONDITIONED PAIN MODULATION. IN THE SECOND PHASE OF THIS PROJECT (UH3), WE WILL EXAMINE THE EFFICACY, IN A LARGER SAMPLE OF INDIVIDUALS WITH OCPA, OF REPEATED LIFU DELIVERY ON MEASURES OF PAIN AND OPIATE CUE-INDUCED CRAVING, ANXIETY SYMPTOMS, INTEROCEPTION AND AUTONOMIC REACTIVITY AS THESE OUTCOMES ARE DYSREGULATED IN OCPA AND ARE MEDIATED BY THE AI. LIFU WILL BE DELIVERED FOR 10 MINUTES EACH HOUR FOR 4 HOURS ON A SINGLE DAY. WE HYPOTHESIZE THAT REPEATED SESSIONS OF LIFU WILL REDUCE MEASURES OF CS, OPIATE CUE-INDUCED CRAVING, STATE ANXIETY SYMPTOMS, INCREASE HEART RATE VARIABILITY AND NORMALIZE MEASURES OF INTEROCEPTION. WE WILL EXAMINE THE DURABILITY AND EFFECT OF 1 VS 2 SESSIONS OF REPEATED LIFU ON THESE OUTCOME MEASURES. REPEATED SESSIONS OF OTHER FORMS OF NEUROMODULATION RESULT IN INCREASED MAGNITUDE AND LONGER LASTING EFFECTS. WE HYPOTHESIZE THAT 2 SESSIONS VS 1 OF REPEATED LIFU WILL RESULT IN GREATER MAGNITUDE OF CHANGE IN THE OUTCOME MEASURES. LASTLY, WE WILL EXAMINE THE SAFETY AND TOLERABILITY OF REPEATED LIFU SESSIONS. THERE IS A NEED FOR IMPROVED TREATMENTS FOR COMPLEX PATIENTS SUCH AS OCPA BEYOND COMBINING TREATMENTS FOR EACH DISORDER. LIFU PROVIDES AN ABILITY TO TRANSIENTLY AND SELECTIVELY INHIBIT AI TO DETERMINE ITS CAUSAL ROLE IN OCPA SYMPTOMS WHICH THEN MAY LEAD TO IMPROVED TREATMENTS FOR THIS CLINICAL TRIAD WHICH IS ASSOCIATED WITH POOR TREATMENT OUTCOMES. | $725K | FY2023 | Sep 2023 – Aug 2025 |
| VA/DoDDepartment of Defense | CEREBROVASCULAR REACTIVITY AND OXYGEN METABOLISM AS MARKERS OF NEURODEGENERATION AFTER TRAUMATIC BRAIN INJURY | $484.6K | FY2016 | Sep 2016 – Sep 2024 |
| VA/DoDDepartment of Defense | ANNEXIN II-DEPENDENT MECHANISM OF BREAST CANCER PROGRESSION | $439K | FY2007 | Jun 2007 – Nov 2011 |
| Department of Health and Human Services | MECHANISM OF CALCIUM PHOSPHATE STONE FORMATION IN ENGINEERED 3D TUBULE | $384.5K | FY2016 | Aug 2016 – Nov 2021 |
| Department of Health and Human Services | FUNCTION OF TRPC3 IN SALIVARY GLAND | $198.7K | FY2010 | May 2010 – Apr 2012 |
Department of Health and Human Services
$9.3M
BELT: BLACKS & EXACERBATIONS ON LABA VS. TIOTROPIUM
Department of Health and Human Services
$1.5M
DUAL ANTIPLATELET THERAPY TRIAL: RESEARCH PROJECT GRANT (R01)
Department of Health and Human Services
$1.1M
CALCIUM TRANSPORT IN KIDNEY PROXIMAL TUBULE AND CALCIUM PHOSPHATE STONE FORMATION
Department of Health and Human Services
$750K
PESBART: EFFECTS OF PHYSICAL ENVIRONMENT AND STRESS IN BLACKS IN RELATION TO ASTH
Department of Health and Human Services
$725K
TOWARDS TREATMENT FOR THE COMPLEX PATIENT: INVESTIGATIONS OF LOW-INTENSITY FOCUSED ULTRASOUND. - OPIOID USE DISORDER WITH CO-MORBID CHRONIC PAIN AND ANXIETY (OCPA) IS A CLINICAL TRIAD ASSOCIATED WITH THE HIGHEST RISK OF OPIATE OVERDOSE DEATHS. CO-OCCURRENCE OF THESE THREE DISORDERS AMPLIFIES SYMPTOMS OF EACH AND RESULTS IN POORER TREATMENT OUTCOMES. THERE ARE SHARED NEUROBIOLOGICAL SUBSTRATES FOR THESE DISORDERS SUCH AS REWARD PROCESSING AND STRESS RESPONSE. THE ANTERIOR INSULA (AI) IS A BRAIN REGION INVOLVED IN THESE PROCESSES AS WELL AS IN CLINICAL DISORDER OF PAIN, ADDICTION, AND ANXIETY. THE AI IS UPREGULATED IN PAIN, ADDICTION AND ANXIETY DISORDERS AND IS THEREFORE A POTENTIAL THERAPEUTIC TARGET FOR NEUROMODULATION. LOW-INTENSITY FOCUSED ULTRASOUND (LIFU) IS A NONINVASIVE METHOD TO INHIBIT CORTICAL AND DEEP BRAIN REGIONS. LIFU CAN REACH DEEP BRAIN REGIONS SUCH AS THE AI WITH SPATIAL SPECIFICITY, UNLIKE TRADITIONAL NONINVASIVE NEUROMODULATION METHODS WHICH LACK SPATIAL SPECIFICITY AND DEPTH PENETRATION. LIFU CAN SELECTIVELY TARGET THE INSULA AND ITS SUBREGIONS AND PROVIDES A POTENTIALLY TRANSFORMATIVE METHOD TO REDUCE SYMPTOMS OF PAIN, OPIATE CRAVING, AND ANXIETY IN A COMPLEX PATIENT POPULATION SUCH AS OCPA. IN THE UG3 PHASE OF THIS STUDY, WE WILL ADMINISTER ONE SESSION OF INHIBITORY LIFU TO THE AI IN INDIVIDUALS WITH OCPA [OPIATE USE DISORDER, CHRONIC BACK PAIN, AND ANXIETY DISORDERS (GENERALIZED ANXIETY DISORDER, POST-TRAUMATIC STRESS DISORDER, OR SOCIAL ANXIETY DISORDER)]. THE AIM OF THIS PHASE OF THE STUDY IS TO ESTABLISH THAT LIFU VS SHAM LIFU TO AI IS SAFE AND WELL TOLERATED AS MEASURED BY ADVERSE EVENTS, CLINICAL EVALUATION AND REPEATED STRUCTURAL BRAIN MAGNETIC RESONANCE IMAGING SCANS. WE WILL ALSO GATHER PRELIMINARY DATA ON THE EFFECT OF LIFU TO AI ON OPIATE CUE-INDUCED CRAVING AND LABORATORY MEASURES OF CENTRAL SENSITIZATION(CS) WHICH OCCURS WITH PAIN CHRONICITY SUCH AS TEMPORAL SUMMATION OF PAIN AND CONDITIONED PAIN MODULATION. IN THE SECOND PHASE OF THIS PROJECT (UH3), WE WILL EXAMINE THE EFFICACY, IN A LARGER SAMPLE OF INDIVIDUALS WITH OCPA, OF REPEATED LIFU DELIVERY ON MEASURES OF PAIN AND OPIATE CUE-INDUCED CRAVING, ANXIETY SYMPTOMS, INTEROCEPTION AND AUTONOMIC REACTIVITY AS THESE OUTCOMES ARE DYSREGULATED IN OCPA AND ARE MEDIATED BY THE AI. LIFU WILL BE DELIVERED FOR 10 MINUTES EACH HOUR FOR 4 HOURS ON A SINGLE DAY. WE HYPOTHESIZE THAT REPEATED SESSIONS OF LIFU WILL REDUCE MEASURES OF CS, OPIATE CUE-INDUCED CRAVING, STATE ANXIETY SYMPTOMS, INCREASE HEART RATE VARIABILITY AND NORMALIZE MEASURES OF INTEROCEPTION. WE WILL EXAMINE THE DURABILITY AND EFFECT OF 1 VS 2 SESSIONS OF REPEATED LIFU ON THESE OUTCOME MEASURES. REPEATED SESSIONS OF OTHER FORMS OF NEUROMODULATION RESULT IN INCREASED MAGNITUDE AND LONGER LASTING EFFECTS. WE HYPOTHESIZE THAT 2 SESSIONS VS 1 OF REPEATED LIFU WILL RESULT IN GREATER MAGNITUDE OF CHANGE IN THE OUTCOME MEASURES. LASTLY, WE WILL EXAMINE THE SAFETY AND TOLERABILITY OF REPEATED LIFU SESSIONS. THERE IS A NEED FOR IMPROVED TREATMENTS FOR COMPLEX PATIENTS SUCH AS OCPA BEYOND COMBINING TREATMENTS FOR EACH DISORDER. LIFU PROVIDES AN ABILITY TO TRANSIENTLY AND SELECTIVELY INHIBIT AI TO DETERMINE ITS CAUSAL ROLE IN OCPA SYMPTOMS WHICH THEN MAY LEAD TO IMPROVED TREATMENTS FOR THIS CLINICAL TRIAD WHICH IS ASSOCIATED WITH POOR TREATMENT OUTCOMES.
Department of Defense
$484.6K
CEREBROVASCULAR REACTIVITY AND OXYGEN METABOLISM AS MARKERS OF NEURODEGENERATION AFTER TRAUMATIC BRAIN INJURY
Department of Defense
$439K
ANNEXIN II-DEPENDENT MECHANISM OF BREAST CANCER PROGRESSION
Department of Health and Human Services
$384.5K
MECHANISM OF CALCIUM PHOSPHATE STONE FORMATION IN ENGINEERED 3D TUBULE
Department of Health and Human Services
$198.7K
FUNCTION OF TRPC3 IN SALIVARY GLAND
Source: Federal Audit Clearinghouse (fac.gov)
No federal single audit records found for this organization.
Single audits are required for entities expending $750,000+ in federal awards annually.
Tax Year 2024 · Source: IRS e-Filed Form 990
Individuals serving as officers, directors, or trustees of the organization.
| Name | Title | Hrs/Wk | Compensation | Related Orgs | Other |
|---|
Source: IRS Publication 78, Auto-Revocation List & e-Postcard Data
Tax-deductible contributions: Yes
Deductibility code: PC
Sources: IRS e-Filed Form 990 (XML) & ProPublica Nonprofit Explorer
Scroll →
| Year | Revenue | Contributions | Expenses | Assets | Net Assets |
|---|---|---|---|---|---|
| 2024IRS e-File | $4.3M | $1.6M | $4.9M | $12.6M | $11.6M |
| 2023 | $4.6M | $2M | $4.4M | $13.3M | $12.2M |
| 2022 | $6.5M | $3.1M | $6M | $14.8M | $11.9M |
| 2021 | $12.6M | $2.1M | $10.8M |
Sources: ProPublica Nonprofit Explorer & IRS e-File Index
| Tax Year | Form Type | Source | Documents |
|---|---|---|---|
| 2024 | 990 | IRS e-File | PDF not yet published by IRSView Filing → |
| 2023 | 990 | DataIRS e-File | PDF not yet published by IRSView Filing → |
| 2022 | 990 | DataIRS e-File |
Financial data: IRS e-Filed Form 990 (Tax Year 2024)
Leadership & compensation: IRS e-Filed Form 990, Part VII (Tax Year 2024)
Federal grants: USAspending.gov (live)
Organization info: IRS Business Master File
Tax-deductibility: IRS Publication 78
| Total |
|---|
| Gail Kerr Md | Chairman | 2 | $0 | $311.3K | $0 | $311.3K |
| Felix Oliver | Executive Director/ceo | 20 | $180.9K | $0 | $1,845 | $182.7K |
Gail Kerr Md
Chairman
$311.3K
Hrs/Wk
2
Compensation
$0
Related Orgs
$311.3K
Other
$0
Felix Oliver
Executive Director/ceo
$182.7K
Hrs/Wk
20
Compensation
$180.9K
Related Orgs
$0
Other
$1,845
Highest compensated employees who are not officers or directors.
| Name | Title | Hrs/Wk | Compensation | Related Orgs | Other | Total |
|---|---|---|---|---|---|---|
| Michael Vjecha | Science Administrator | 40 | $179.1K | $0 | $18.9K | $198.1K |
| Adriana Sanchez | Id Research Manager | 40 | $149.2K | $0 | $15.5K | $164.7K |
Michael Vjecha
Science Administrator
$198.1K
Hrs/Wk
40
Compensation
$179.1K
Related Orgs
$0
Other
$18.9K
Adriana Sanchez
Id Research Manager
$164.7K
Hrs/Wk
40
Compensation
$149.2K
Related Orgs
$0
Other
$15.5K
Members of the governing board. Board members often serve without compensation.
| Name | Title | Hrs/Wk | Compensation | Related Orgs | Other | Total |
|---|---|---|---|---|---|---|
| Angelike Liappis Md | Director | 1 | $0 | $268.9K | $0 | $268.9K |
| Bidhan Bandyopadhyay Phd | Director | 1 | $0 | $153.4K | $0 | $153.4K |
| Charles Faselis Md | Director | 1 | $0 | $324.5K | $0 | $324.5K |
| Col Ret Michael S Heimall | Director | 1 | $0 | $230.4K | $0 | $230.4K |
| Daniel Taub Phd | Director | 1 | $0 | $191.9K | $0 | $191.9K |
| Joao Ascensao Md |
Angelike Liappis Md
Director
$268.9K
Hrs/Wk
1
Compensation
$0
Related Orgs
$268.9K
Other
$0
Bidhan Bandyopadhyay Phd
Director
$153.4K
Hrs/Wk
1
Compensation
$0
Related Orgs
$153.4K
Other
$0
Charles Faselis Md
Director
$324.5K
Hrs/Wk
1
Compensation
$0
Related Orgs
$324.5K
Other
$0
| $20.6M |
| $11.6M |
| 2020 | $6.2M | $6.1M | $6.3M | $13.5M | $9.8M |
| 2019 | $2.5M | $2.5M | $3.1M | $10.3M | $9.9M |
| 2018 | $4.5M | $4.4M | $3.8M | $11M | $10.5M |
| 2017 | $8M | $8M | $8.5M | $12.3M | $9.8M |
| 2016 | $9.9M | $9.9M | $9.2M | $12.8M | $10.3M |
| 2015 | $10.9M | $10.9M | $9.8M | $12M | $9.6M |
| 2014 | $12.1M | $12.1M | $9.6M | $11.1M | $8.5M |
| 2013 | $11.7M | $11.7M | $10.3M | $5.5M | $5.5M |
| 2012 | $6.7M | $6.7M | $7.5M | $4.1M | $4.1M |
| 2011 | $6.9M | $6.9M | $5.1M | $4.9M | $4.9M |
| 2021 | 990 | Data |
| 2020 | 990 | Data | PDF not yet published by IRS |
| 2019 | 990 | Data |
| 2018 | 990 | Data |
| 2017 | 990 | Data |
| 2016 | 990 | Data |
| 2015 | 990 | Data |
| 2014 | 990 | Data |
| 2013 | 990 | Data |
| 2012 | 990 | Data |
| 2011 | 990 | Data |
| 2010 | 990 | — |
| 2009 | 990 | — |
| 2008 | 990 | — |
| 2007 | 990 | — |
| 2006 | 990 | — |
| 2005 | 990 | — |
| 2004 | 990 | — |
| 2003 | 990 | — |
| 2002 | 990 | — |
| Director |
| 1 |
| $0 |
| $80K |
| $0 |
| $80K |
| Matthew Tuck Md | Director | 1 | $0 | $283.8K | $0 | $283.8K |
| Melvin Goodweather | Director | 1 | $0 | $0 | $0 | $0 |
| Pamela Karasik Md | Director | 1 | $0 | $395.7K | $0 | $395.7K |
| Samantha Mcintosh Md | Director | 1 | $0 | $321.2K | $0 | $321.2K |
| Samir Patel Md | Director | 1 | $0 | $328.3K | $0 | $328.3K |
Col Ret Michael S Heimall
Director
$230.4K
Hrs/Wk
1
Compensation
$0
Related Orgs
$230.4K
Other
$0
Daniel Taub Phd
Director
$191.9K
Hrs/Wk
1
Compensation
$0
Related Orgs
$191.9K
Other
$0
Joao Ascensao Md
Director
$80K
Hrs/Wk
1
Compensation
$0
Related Orgs
$80K
Other
$0
Matthew Tuck Md
Director
$283.8K
Hrs/Wk
1
Compensation
$0
Related Orgs
$283.8K
Other
$0
Melvin Goodweather
Director
$0
Hrs/Wk
1
Compensation
$0
Related Orgs
$0
Other
$0
Pamela Karasik Md
Director
$395.7K
Hrs/Wk
1
Compensation
$0
Related Orgs
$395.7K
Other
$0
Samantha Mcintosh Md
Director
$321.2K
Hrs/Wk
1
Compensation
$0
Related Orgs
$321.2K
Other
$0
Samir Patel Md
Director
$328.3K
Hrs/Wk
1
Compensation
$0
Related Orgs
$328.3K
Other
$0